drugset / Trial / NCT03631043
Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This early phase I trial studies the side effects of personalized vaccine in treating patients with smoldering multiple myeloma. Vaccines made from a person's blood and bone marrow may help the body build an effective immune response to kill cancer cells.
Timeline
- Start
- 2018-12-21
- Primary completion
- 2025-12-10
- Completion
- 2025-12-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | — | Oral |
| Subject | Vaccine Therapy | Vaccine | — | Subcutaneous |